# AZD5492

Source: https://onco.cc/drugs/azd5492/  
OnCo record `azd5492` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

AZD5492 is an experimental T-cell engager from AstraZeneca in phase 2 trials, aimed at CD20.

## Summary

AZD5492 is a T-cell engager developed by AstraZeneca. Its target is CD20 (the sponsor names CD20). The sponsor states: A CD8/TCR-based T-cell engaging antibody targeting CD20, administered subcutaneously to redirect T cells against CD20-positive B-cell malignancies. ClinicalTrials.gov describes the intervention as: CD8/TCR based T-cell engaging antibody targeting CD20, which is administered subcutaneously. It is the investigational product in 1 recruiting or active industry-led phase 2 and phase 3 interventional cancer trial. The largest, NCT06542250, plans to enrol 174 participants with primary completion expected 2029-12-18. Status reflects the highest phase registered on ClinicalTrials.gov; no efficacy results are recorded here.

## Fields

- Kind: Treatment
- Status: phase-2
- Last checked: 2026-09-11
- Tags: pipeline; ctgov-ingest
- Modality: T-cell engager
- Mechanism: A CD8/TCR-based T-cell engaging antibody targeting CD20, administered subcutaneously to redirect T cells against CD20-positive B-cell malignancies.

## Sources

- ClinicalTrials.gov: trials of AZD5492: https://clinicaltrials.gov/search?intr=AZD5492

## Connected records

- targets: [CD20](https://onco.cc/targets/cd20/)
- companies: [AstraZeneca](https://onco.cc/companies/astrazeneca/)
- trials: [A Study to Evaluate Safety, PK, PD and Efficacy of AZD5492, a T Cell-engaging Antibody Targeting CD20 in Subjects With R/R B-Cell Malignancies.](https://onco.cc/trials/nct06542250/)

---
JSON: https://onco.cc/api/v1/entities/azd5492.json